Yabe Daisuke, Seino Yutaka
Division of Diabetes, Clinical Nutrition and Endocrinology, Department of Internal Medicine, Kansai Electric Power Hospital.
Nihon Rinsho. 2011 May;69(5):946-50.
Immunoassays for incretin hormones, GLP-1 and GIP are critical to study their secretion and DPP-4-processing in vivo, as well as to evaluate therapeutic efficacies of current and future incretin-based drugs in patients with diabetes. However, large variability in levels of incretins, especially intact GLP-1, determined by various immunoassays hampers our understanding of the incretin biology. Recent studies have revealed an importance of an ethanol or solid-phase extraction prior to immunoassays for intact GLP-1. The extraction removes interferences with unknown identity from plasma to obtain results less variable among different subjects. The extraction improves correlation across the different immunoassays for intact GLP-1. Here, we summarize current knowledge and potential problems regarding immunoassays for GLP-1 and GIP.
用于检测肠促胰岛素激素、胰高血糖素样肽-1(GLP-1)和葡萄糖依赖性促胰岛素多肽(GIP)的免疫测定法对于研究它们在体内的分泌和二肽基肽酶-4(DPP-4)加工过程,以及评估当前和未来基于肠促胰岛素的药物对糖尿病患者的治疗效果至关重要。然而,通过各种免疫测定法测定的肠促胰岛素水平,尤其是完整的GLP-1水平存在很大差异,这妨碍了我们对肠促胰岛素生物学的理解。最近的研究表明,在对完整的GLP-1进行免疫测定之前进行乙醇或固相萃取很重要。这种萃取可去除血浆中身份不明的干扰物,从而获得不同受试者之间变异性较小的结果。这种萃取提高了针对完整GLP-1的不同免疫测定法之间的相关性。在此,我们总结了关于GLP-1和GIP免疫测定法的当前知识和潜在问题。